The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
Pharma stocks are healthcare stocks, but healthcare stocks cover a much broader range of businesses. Under the Global Industry Classification Standard (GICS), pharmaceuticals are one sub-industry within the Health Care sector, alongside businesses such as medical-device makers, hospitals, insurers, and life-sciences research suppliers. That distinction matters when you compare a company, sector index, or fund: a broad healthcare investment is not necessarily a concentrated bet on drugmakers.
At a glance
| Name | Scope | Main business exposure | Key distinction | Checked |
|---|---|---|---|---|
| Pharma stocks | A sub-industry within GICS Health Care | Researching, developing, or producing pharmaceutical products, including active pharmaceutical ingredients and veterinary drugs | Drug products, development programs, competition, and product protection can shape results | November 2026 |
| Healthcare stocks | The wider GICS Health Care sector | Pharma plus providers, facilities, devices, supplies, managed care, health technology, biotech, and life-sciences tools and services | Includes several distinct business models; exposure depends on the companies held | November 2026 |
What is the difference between pharma stocks and healthcare stocks?
Pharma stocks are a subset of healthcare stocks. “Healthcare stocks” is the umbrella category; it can include drugmakers, but it also includes companies that provide care, make medical equipment, administer health plans, or supply research tools.
As an Amazon Associate I earn from qualifying purchases.
In GICS, pharmaceuticals sits within the Health Care sector. The classification is designed to group companies by their principal business activity, not to say that every business in one sector operates alike. A company may also have multiple product lines or revenue sources, so its label is a starting point—not a complete description of its financial exposure.
The distinction is useful because a fund or index described as healthcare may hold a mix of businesses whose revenues respond to different forces. A pharma company may depend heavily on a drug portfolio and its development pipeline. A hospital operator, managed-care company, or diagnostic-equipment maker has different customers, operations, and sources of risk. The label alone does not reveal the mix.
Popular on Amazon
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
What businesses count as healthcare stocks?
GICS divides Health Care into several areas beyond pharmaceuticals. The February 2025 MSCI GICS methodology describes classifications covering equipment and devices, supplies, distributors, healthcare services and facilities, managed health care, health care technology, biotechnology, pharmaceuticals, and life-sciences tools and services.
- Pharmaceuticals: Companies engaged in researching, developing, or producing pharmaceutical products. GICS includes active pharmaceutical ingredients and veterinary drugs in this sub-industry.
- Biotechnology: A distinct GICS sub-industry. It is related to medicine and drug development, but it is not the same classification as pharmaceuticals.
- Equipment and devices: Businesses that make equipment used in diagnosis or treatment. State Street Global Advisors’ sector explainer gives devices used in diagnosis and treatment as a plain-language example.
- Supplies and distributors: Businesses supplying or distributing healthcare-related products.
- Providers, services, and facilities: Businesses such as hospitals and clinics, as well as other services. State Street also gives lab testing as an example of a healthcare service.
- Managed health care: Companies involved in managing health plans and related services.
- Health care technology: Technology-focused businesses classified within the sector.
- Life-sciences tools and services: Companies supplying tools and services used in scientific and medical research.
These are classification examples, not a substitute for checking a particular issuer’s disclosures. GICS is hierarchical: S&P Dow Jones Indices described it in 2021 as having 11 sectors, 24 industry groups, 69 industries, and 158 sub-industries. Those numbers describe the taxonomy, not the count of healthcare companies. The S&P Health Care primer explains that classification considers quantitative and qualitative factors, including revenue, earnings, and market perception.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsWhy can two healthcare stocks behave differently?
The sector label groups businesses by principal activity; it does not make their economics interchangeable. A drugmaker’s prospects may depend on its marketed products, development programs, competition, product exclusivity, and pricing or payer conditions. A provider, insurer, device maker, or research-tool supplier has a different operating model and revenue base.
That means a broad statement such as “healthcare is defensive” or “pharma is risky” can conceal important differences. The cited material does not support a universal ranking of these subsectors as safer or more profitable. Even within pharmaceuticals, individual companies can have very different product portfolios, pipeline exposure, and concentration in particular products or markets.
For a pharma company, development setbacks or regulatory decisions may affect a future product’s prospects; competition and pricing pressure may affect sales; and the expiration or loss of intellectual-property rights or regulatory exclusivity may expose products to competition. These are risks to examine for a specific issuer, not a claim that every drugmaker has the same risks or degree of exposure. In its 2024 Form 10-K, Pfizer discusses risks involving product safety, regulation, competition, and intellectual-property rights and exclusivity. That filing illustrates disclosures by one company; it is not evidence that every healthcare business faces those same exposures.
Also popular on Amazon
Other healthcare businesses have their own drivers. A provider’s revenue comes from delivering care or services; a device business depends on its product markets and customers; and a managed-care company is not economically equivalent to a manufacturer selling medicines. To understand a stock, look through the sector name to the company’s actual products, services, customers, and revenue sources.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →How pharma companies make money—and where that model can change
A pharma stock can represent several stages of one chain: research, development, manufacturing, and sales of medicines. Some revenue may come from established products, while future growth may depend on development programs that have not yet reached the market. The balance between current products and future programs is therefore an important part of the investment case.
Product protection is another central question. Patents and regulatory exclusivity can limit direct competition for a period, while loss, expiration, or invalidation of those rights can change the competitive setting. Pfizer’s 2024 filing says such events can materially affect revenues. For an individual company, review which products contribute most to sales, when relevant protection is scheduled to change, and whether replacement products or programs are being developed.
Competition can arise from other branded products, alternative treatments, or products that become available after protection ends. Pricing and payer conditions can also influence the amount a company realizes from sales. These factors should be tied to the company’s actual portfolio and markets rather than generalized to every pharma issuer.
How non-pharma healthcare businesses earn revenue
The wider sector contains businesses with fundamentally different customers and cash-flow patterns. A hospital or clinic operator earns revenue by delivering care. A laboratory service earns revenue from testing. A device maker sells equipment used in diagnosis or treatment, often through customer and procurement relationships that differ from medicine sales. A distributor supplies products to other participants in the healthcare system. A managed-care company administers health plans and related services. A life-sciences tools supplier sells instruments, consumables, or services used in research.
Also popular on Amazon
Health care technology companies are another distinct category under GICS. Their products and customers may not resemble either a drugmaker or a hospital. Biotechnology is also separate from pharmaceuticals in the classification system, even though both can be involved in medicine and drug development. These examples show why “healthcare” is not one uniform operating model.
When comparing two companies, ask what is actually sold, who pays, how recurring the demand is, and which operational or regulatory events can interrupt revenue. The answers should come from the issuer’s filings and disclosures, not only from a financial website’s sector tag.
A comparison framework for two healthcare stocks
Use the following sequence to make a company-to-company comparison. It is a set of investigation questions, not a scoring system that automatically identifies the better investment.
- Define the principal business. Write a one-sentence description of the products or services that generate the company’s revenue. Then check whether that description matches its GICS classification. If the issuer has several divisions, list each material activity instead of forcing it into a single label.
- Map current revenue and future revenue. Separate products or services already being sold from development programs, planned launches, or technologies still being built. A pharma company may have marketed medicines and a development pipeline; a device or technology company may have a different product-development timetable.
- Identify the decision makers and payers. Determine whether revenue depends on patients, hospitals, laboratories, insurers, governments, distributors, or research organizations. The relevant payer and reimbursement questions differ across these models.
- Review regulatory exposure. Note which approvals, safety requirements, operating rules, or payment arrangements could affect the business. A drugmaker’s regulatory issues are not interchangeable with those of a hospital, managed-care company, or device supplier.
- Examine protection and competition. For protected products, review patent and regulatory-exclusivity schedules. For devices, services, or technology, examine competitive alternatives and customer switching considerations disclosed by the issuer. In every case, ask how quickly a rival could affect sales.
- Measure concentration. Look for dependence on a small number of products, customers, facilities, geographies, or contracts. Concentration can make one product event or customer decision especially important, even when the company is classified in a broad sector.
- Check the company’s own risk language. Annual reports describe the risks management considers material. Pfizer’s 2024 Form 10-K is an example of an issuer discussing safety, regulation, competition, and intellectual-property rights; use it as an illustration, not as a template for every company.
- Compare valuation only after understanding the model. A sales or earnings comparison is meaningful only when the businesses, revenue sources, and development stages are understood. The available material does not provide a common metric for ranking all healthcare subsectors.
What risks are common, and what risks are company-specific?
| Question | Why it matters for pharma | Why it differs elsewhere in healthcare |
|---|---|---|
| Development | Future medicines may depend on development programs and regulatory decisions. | Devices, services, and tools have their own product or technology development cycles. |
| Competition | Rivals, alternatives, and post-exclusivity competition can affect product sales. | Providers, insurers, and suppliers face competition shaped by customers, contracts, and service capabilities. |
| Pricing and reimbursement | Payer conditions and pricing pressure can influence medicine revenue. | Payment arrangements also matter to care providers and managed-care businesses, but the mechanics differ. |
| Concentration | A few products may account for a substantial share of revenue. | Other companies may instead depend on a few customers, facilities, contracts, or device platforms. |
| Protection | Patent or regulatory-exclusivity changes can alter the competitive environment. | Non-pharma businesses may have different forms of differentiation and do not share the same patent timetable. |
This table is a checklist, not a prediction. A company can have more than one exposure, and the degree of risk must be established from its own disclosures.
Does a healthcare index give you pharma exposure?
It can, but a broad healthcare index is not a pure pharma index. S&P Dow Jones Indices describes the S&P Global 1200 Health Care as comprising Global 1200 constituents classified in the GICS Health Care sector. Because the sector includes multiple sub-industries, the index name alone does not establish that it tracks only drugmakers.
Also popular on Amazon
Index composition can also change. AllianceBernstein reported that pharma stocks represented 82% of the MSCI World Health Care Index in 2000 and 45% as of May 31, 2026, citing MSCI and AllianceBernstein. This is historical composition context—not a performance forecast or a promise about future weights. It also refers to that specific index, not every healthcare benchmark.
An index is a benchmark; an investable fund is a separate product designed to track or otherwise use an index or strategy. Before treating a fund as a way to obtain a particular exposure, check its current holdings, stated methodology, geographic scope, and fees. Those details can differ between funds even when their names sound similar.
How to check a fund before buying
- Read the mandate. Determine whether the fund follows the broad GICS Health Care sector, a narrower pharmaceutical grouping, or an actively selected strategy.
- Inspect current holdings. Look at the largest positions and the distribution across pharmaceuticals, biotechnology, providers, devices, managed care, technology, and tools. Holdings can change, so use the most recent portfolio information.
- Check geography. The S&P Global 1200 Health Care example uses constituents from major markets through the parent Global 1200. Another fund may have a different country or market scope.
- Review methodology and rebalancing information. Understand how constituents are selected, classified, weighted, and changed. Historical weights such as the MSCI World Health Care figures do not guarantee future composition.
- Compare stated fees. A fund’s expenses affect the cost of obtaining exposure. Compare the disclosed fee information alongside holdings and methodology rather than choosing by name alone.
A benchmark can describe a market segment without being directly purchasable. A fund may track a benchmark, sample it, or use a different process. Confirm the actual product documents before assuming that an index statistic describes your investment.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Common mistakes when comparing pharma and healthcare stocks
- Treating the words as synonyms. Pharma is one sub-industry; healthcare is the broader sector.
- Assuming every healthcare fund is diversified across the same businesses. Two funds with similar names can have different holdings, geography, fees, and methodologies.
- Using one company’s risks as a sector rule. Pfizer’s filing documents Pfizer’s exposures. It does not establish that every healthcare company has the same risks or magnitude of exposure.
- Ignoring biotechnology’s separate classification. Biotech and pharmaceuticals are distinct GICS sub-industries, even where their activities overlap.
- Confusing historical index composition with a forecast. The 82% and 45% figures describe the MSCI World Health Care Index at the stated dates; they do not predict returns or future weights.
- Relying on a label instead of revenue evidence. Principal-activity classification is useful, but a company can have complex and changing revenue sources.
- Looking only at products and not payers or customers. Pricing, reimbursement, customer concentration, and contractual relationships can matter as much as the product category.
What should you take away before comparing stocks or funds?
Use “pharma” to describe the narrower drug-related category and “healthcare” for the broader sector. Then inspect the actual company or fund: its revenue mix, business model, development or product exposure, competitive position, and—if it is a fund—holdings and methodology. A category name helps you sort an investment; it does not answer whether that investment fits your goals or how it will perform.
The practical distinction is scope. A pharma comparison centers on medicines, development programs, exclusivity, competition, and payer or pricing conditions. A healthcare comparison may involve any combination of drugmakers, biotech companies, providers, facilities, managed care, devices, supplies, technology, distributors, and life-sciences tools. Start with the classification, then verify the issuer’s business and the fund’s documents.
Also popular on Amazon
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Frequently Asked Questions
Is biotechnology the same as pharmaceuticals in stock classifications?
No. In GICS, biotechnology and pharmaceuticals are separate sub-industries within Health Care. A company’s products and principal business activity determine the relevant classification, so check its issuer information rather than assuming the two labels are interchangeable.
Can a healthcare fund have little exposure to drugmakers?
Yes. The healthcare sector includes several non-pharma sub-industries, and a fund’s holdings determine its actual exposure. Review the fund’s current portfolio and methodology instead of relying on its name alone.
Why do index weights for pharma change over time?
An index’s constituents and their relative weights can change as market values and classifications change, among other index-methodology factors. The reported historical share is specific to the named index and date; it does not establish what the share will be later.
Where can I verify how a company is classified?
Check the company’s filings and investor disclosures for its business and revenue mix, then consult the index provider’s methodology if the classification matters to a benchmark or fund. A classification is based on principal activity and may not capture every aspect of a company’s operations.
Are all pharma stocks exposed to patent expirations in the same way?
No. Exposure depends on the products a company sells, the relevant patent or regulatory-exclusivity schedules, the importance of those products to revenue, and the competitive alternatives. Review the individual issuer’s disclosures.
The Bottom Line
Pharma stocks are one part of the broader healthcare sector. Compare the underlying business, revenue mix, development and protection risks, customers, and competitive pressures—and verify a fund’s holdings, methodology, geography, and fees—before drawing conclusions from the label.
